Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenkefu
- Development stage
- Phase 2
- Lead developer
- Chengdu Nanshan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shenkefu (also known as Shenkefu Granules) is a proprietary traditional Chinese medicine (TCM) developed by Chengdu Nanshan Pharmaceutical Co., Ltd. for the treatment of chronic kidney disease, specifically diabetic nephropathy. It is formulated as oral granules and is indicated for patients exhibiting "Qi and Yin deficiency" and "blood stasis" patterns, which are common clinical presentations in progressive renal damage. The therapeutic mechanism of Shenkefu involves the modulation of multiple signaling pathways; it primarily acts by inhibiting the expression of transforming growth factor beta-1 (TGF-beta1) to reduce renal interstitial fibrosis and suppressing nuclear factor kappa B (NF-kappaB) to alleviate renal inflammation. Clinical studies, including Phase II and Phase III trials in China, have demonstrated its efficacy in reducing urinary protein excretion, improving renal function parameters, and slowing the progression of kidney disease in diabetic patients.
- Brand names
- ShenkefuShenkefu Granules
- Other names
- Shenkefu Keli肾渴复颗粒
02
Targets
CASP3 (Caspase-3)IL1B (Interleukin-1 beta)NFKBIA (NFKB inhibitor alpha)NF-κBTGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on Shenkefu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenkefu.